OTT_A_226404 10487..10493

Jiaxin Wang Yangchun Xu Yanjun Wang Xuan Zhang Guizhen Zhang 1Department of Endocrinology, The Second Hospital of Jilin University, Changchun, People’s Republic of China; 2Jilin Provincial Key Laboratory on Molecular and Chemical Genetic, The Second Hospital of Jilin University, Changchun, People’s Republic of China Purpose: It has been reported that circulating levels of IgG antibodies against p16, CD25 and FOXP3 proteins were significantly changed in patients with lung cancer, breast cancer and esophageal cancer. However, different peptide fragments appear to trigger different immune responses. This work aimed to analyze the alteration of plasma IgG for p16-derived peptide antigen called p16a, CD25-derived peptide antigen called CD25a and a FOXP3-derived antigen in hepatocellular carcinoma (HCC). Patients and methods: An enzyme-linked immunosorbent assay (ELISA) was developed in-house to detect plasma IgG to p16a, CD25a and FOXP3 in 119 patients with HCC and 132 control subjects. Results: Circulating levels of IgG antibodies for all three peptide antigens were significantly higher in HCC patients than control subjects (P<0.001 for all 3 assays); male patients mainly contributed to increase (P<0.01 for all 3 assays). Further analysis showed that plasma antip16a, anti-CD25a and anti-FOXP3 IgG levels were increased mainly in patients with intermediate and late-stage HCC (P<0.01 for both assays). Receiver operating characteristic (ROC) curve analysis showed that with a specificity of >95%, the area under the ROC curve (AUC) was 0.62 with 11.4% sensitivity for anti-p16a assay, 0.68 with 14.3% sensitivity for anti-CD25a IgG assay and 0.64 with 10.1% sensitivity for anti-FOXP3 assay. Of the three groups of HCC patients, group 3 (BCLC stage C+D) showed the best sensitivity for the detection of plasma anti-p16a and anti-FOXP3 IgG levels with an AUC of 0.66 and 0.65. Conclusion: Circulating IgG antibody to p16a, CD25a and FOXP3 proteins may be a useful biomarker for assessment of HCC prognosis of this malignancy, especially in male patients with HCC.

[1]  Xuan Zhang,et al.  Circulating anti‐p16a IgG autoantibodies as a potential prognostic biomarker for non‐small cell lung cancer , 2018, FEBS open bio.

[2]  Wenjing Xie,et al.  Alteration of circulating natural autoantibodies to CD25-derived peptide antigens and FOXP3 in non-small cell lung cancer , 2018, Scientific Reports.

[3]  D. St. Clair,et al.  Study of Novel Autoantibodies in Schizophrenia , 2018, Schizophrenia bulletin.

[4]  Yangchun Xu,et al.  Change of circulating antibodies against CD25-derived peptide antigen in hepatocellular carcinoma. , 2017, Journal of Cancer Research and Therapeutics.

[5]  Q. Gao,et al.  FOXP3 Is a HCC suppressor gene and Acts through regulating the TGF-β/Smad2/3 signaling pathway , 2017, BMC Cancer.

[6]  D. Clair,et al.  A study of type-1 diabetes associated autoantibodies in schizophrenia , 2016, Schizophrenia Research.

[7]  Mathieu Laversanne,et al.  International trends in liver cancer incidence, overall and by histologic subtype, 1978–2007 , 2016, International journal of cancer.

[8]  W. Guo,et al.  Association of preoperative EpCAM Circulating Tumor Cells and peripheral Treg cell levels with early recurrence of hepatocellular carcinoma following radical hepatic resection , 2016, BMC Cancer.

[9]  Yibing Chen,et al.  High leukocyte mtDNA content contributes to poor prognosis through ROS-mediated immunosuppression in hepatocellular carcinoma patients , 2016, Oncotarget.

[10]  Weili Wang,et al.  Further study of circulating IgG antibodies to CD25‐derived peptide antigens in nonsmall cell lung cancer , 2016, FEBS open bio.

[11]  Shilong Sun,et al.  Anti‐p16 autoantibodies may be a useful biomarker for early diagnosis of esophageal cancer , 2015, Asia-Pacific journal of clinical oncology.

[12]  Tong Liu,et al.  Circulating antibodies to p16 protein-derived peptides in breast cancer. , 2015, Molecular and clinical oncology.

[13]  Tong Liu,et al.  Study of circulating antibodies against CD25 and FOXP3 in breast cancer , 2014, Tumor Biology.

[14]  L. Ye,et al.  Autoantibodies against p16 protein-derived peptides may be a potential biomarker for non-small cell lung cancer , 2014, Tumor Biology.

[15]  L. Ye,et al.  Circulating IgG antibody against FOXP3 may be a potential biomarker for lung cancer , 2013 .

[16]  L. Ye,et al.  A study of circulating anti-CD25 antibodies in non-small cell lung cancer , 2013, Clinical and Translational Oncology.

[17]  Shimon Sakaguchi,et al.  The plasticity and stability of regulatory T cells , 2013, Nature Reviews Immunology.

[18]  L. Ye,et al.  Circulating autoantibody to FOXP3 may be a potential biomarker for esophageal squamous cell carcinoma , 2013, Tumor Biology.

[19]  K-H Lee,et al.  Circulating autoantibody to CD25 may be a potential biomarker for early diagnosis of esophageal squamous cell carcinoma , 2013, Clinical and Translational Oncology.

[20]  A. Ghaderi,et al.  Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC). , 2012, Lung cancer.

[21]  Hong-yan Cheng,et al.  Expression of p16 in non-small cell lung cancer and its prognostic significance: a meta-analysis of published literatures. , 2011, Lung cancer.

[22]  Leida Zhang,et al.  Increased liver-infiltrating CD8+FoxP3+ regulatory T cells are associated with tumor stage in hepatocellular carcinoma patients. , 2010, Human immunology.

[23]  D. Hafler,et al.  FOXP3+ regulatory T cells in the human immune system , 2010, Nature Reviews Immunology.

[24]  Peter Malfertheiner,et al.  Promoter methylation of CDKN2A and lack of p16 expression characterize patients with hepatocellular carcinoma , 2010, BMC Cancer.

[25]  Ti Zhang,et al.  Increased prevalence of regulatory T cells in the tumor microenvironment and its correlation with TNM stage of hepatocellular carcinoma , 2010, Journal of Cancer Research and Clinical Oncology.

[26]  M. Manns,et al.  Low-dose Cyclophosphamide Treatment Impairs Regulatory T Cells and Unmasks AFP-specific CD4+ T-cell Responses in Patients With Advanced HCC , 2010, Journal of immunotherapy.

[27]  F. Shi,et al.  Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. , 2006, Oncology reports.

[28]  R. Carsetti,et al.  Peripheral development of B cells in mouse and man , 2004, Immunological reviews.

[29]  R. Sutherland,et al.  Overexpression of the cell cycle inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  Siyao Li,et al.  Detecting of p16 Autoantibody as a Potential Early Diagnostic Serum Biomarker in Patients with Cervical Cancer. , 2016, Clinical Laboratory.

[31]  Xuan Peng,et al.  Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma. , 2007, Journal of hepatology.